WebAug 3, 2024 · Gilead’s cell therapy business outperformed Wall Street expectations during the second quarter. The unit — which currently consists of two products, Yescarta and Tecartus, used to treat various blood cancers — generated $368 million in the three-month period, an increase of 68% year over year, earnings numbers released Tuesday show. … WebApr 13, 2024 · Gilead Sciences, Inc. has a 52-week low of $57.17 and a 52-week high of $89.74. The stock's fifty day simple moving average is $82.06 and its 200-day simple moving average is $80.60. 3 High Dividend Stocks to Buy and Hold; Gilead Sciences (NASDAQ:GILD - Get Rating) last released its earnings results on Thursday, February …
Québec Provides Access to Biktarvy® for the Treatment of HIV
WebApr 11, 2024 · Gilead Sciences (NASDAQ:GILD - Get Rating) last posted its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.17. Gilead Sciences had a return on equity of 44.46% and a net margin of 16.83%. WebOct 27, 2024 · Webcast. Q3 2024 Earnings Release. Q3 2024 Presentation. Q3 2024 Supplementary Information. Q3 2024 Prepared Remarks. Q3 2024 Summary of … clovis animal shelter on villa
Signaturefd LLC Purchases 2,441 Shares of Gilead Sciences, Inc.
WebFeb 1, 2024 · As of December 31, 2024, Gilead had $7.8 billion of cash, cash equivalents and marketable debt securities compared to $7.9 billion as of December 31, 2024. During the fourth quarter 2024, Gilead generated $3.2 billion in operating cash flow. During the fourth quarter 2024, Gilead repaid $1.0 billion in debt, paid cash dividends of $894 million ... WebFeb 2, 2024 · Fourth Quarter & Full Year 2024 Gilead Sciences Earnings Conference Call. Feb 2, 2024 4:30 PM ET. Webcast. Q4 2024 Earnings Release. Q4 2024 Presentation. Q4 2024 Supplementary Information. Q4 2024 Prepared Remarks. Q4 2024 Summary of … Web1 day ago · Gilead Sciences will be looking to display strength as it nears its next earnings release. On that day, Gilead Sciences is projected to report earnings of $1.62 per share, which would represent a ... clovis ancient history